Sofosbuvir and daclatasvir compared with standard of care in the treatment of patients admitted to hospital with moderate or severe coronavirus infection (COVID-19): a randomized controlled trial

BACKGROUND: Currently no effective antiviral therapy has been found to treat COVID-19. The aim of this trial was to assess if the addition of sofosbuvir and daclatasvir improved clinical outcomes in patients with moderate or severe COVID-19. METHODS: This was an open-label, multicentre, randomized c...

詳細記述

保存先:
書誌詳細
出版年:J Antimicrob Chemother
主要な著者: Sadeghi, Anahita, Ali Asgari, Ali, Norouzi, Alireza, Kheiri, Zahedin, Anushirvani, Amir, Montazeri, Mahnaz, Hosamirudsai, Hadiseh, Afhami, Shirin, Akbarpour, Elham, Aliannejad, Rasoul, Radmard, Amir Reza, Davarpanah, Amir H, Levi, Jacob, Wentzel, Hannah, Qavi, Ambar, Garratt, Anna, Simmons, Bryony, Hill, Andrew, Merat, Shahin
フォーマット: Artigo
言語:Inglês
出版事項: Oxford University Press 2020
主題:
Original Research
オンライン･アクセス:https://ncbi.nlm.nih.gov/pmc/articles/PMC7454592/
https://ncbi.nlm.nih.gov/pubmed/32812039
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/jac/dkaa334
タグ: タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!

類似資料